AI-generated summary
The authors reviewed clinical and preclinical studies of near-infrared and red light (photobiomodulation) for major depressive disorder, drawing on a 2015 PubMed search. They report that preliminary clinical evidence and links to metabolism, inflammation, oxidative stress and neurogenesis suggest possible promise, but describe the approach as experimental and call for large randomized controlled trials.
- Who or what was studied
- Adults with major depressive disorder, with some clinical and preclinical studies on related conditions such as anxiety, suicidal ideation and traumatic brain injury
- Limits stated in the abstract
- The abstract states that the evidence is preliminary and experimental and that large randomized controlled trials are still needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on spiedigitallibrary.org.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Oxidative stress, Inflammation, Transcranial photobiomodulation, Near-infrared, Depression, Low-level laser therapy, Traumatic brain injury. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.